PPTA Announcement: DLA Piper to Provide Federal Legislative Representation
ANNAPOLIS, MD—The Plasma Protein Therapeutics Association (PPTA) is pleased to announce that DLA Piper will provide federal legislative representation. DLA Piper brings specialized expertise on legislative and regulatory affairs affecting the entire spectrum of the life sciences community, and has a track record of successful advocacy that adheres to PPTA’s priorities of improving patient access and enhancing the biomedical innovation environment.
Julie Birkofer, PPTA Senior Vice President, North America commented, "Through our partnership with DLA Piper, PPTA will elevate for Congressional leadership the Association’s priorities, and build support across Washington for policies that benefit the rare disease patients who rely on plasma protein therapies for their lifesaving treatment.”
“We are delighted to initiate our partnership with PPTA, and we look forward to counseling the association on the broad array of complex issues arising from the unique nature and position of the industry,” said Mary B. Langowski, Partner, Chair, Health Care Policy and Regulatory Practice, DLA Piper.
The DLA Piper consulting team includes dedicated healthcare professionals, many of whom have served on key congressional committees, health policy think tanks, NIH, CMS, and FDA. In collaboration with the experts at DLA Piper, PPTA will work closely with Congress and federal health agencies to anticipate and guide the content and impact of statutes, regulations, rules and guidelines.